Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (19)
Bernd Bokemeyer, Sandra Plachta‐Danielzik, Romina di Giuseppe, Ulf Helwig, Niels Teich, Carsten Schmidt, Petra Hartmann, Christina Sobotzki & Stefan Schreiber. (2023) Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5‐year follow‐up data from the prospective BioCrohn study. Alimentary Pharmacology & Therapeutics 58:1, pages 35-47.
Crossref
Crossref
Johan Burisch. (2023) Long‐term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort. APMIS 131:S147, pages 1-46.
Crossref
Crossref
Aditi Kumar, Nuha Yassin, Alexandra Marley, Vittoria Bellato, Caterina Foppa, Gianluca Pellino, Pär Myrelid, Monica Millan, Beatriz Gros, Nicolas Avellaneda, Ignacio Catalan-Serra, Alaa El-Hussuna, João A. Cunha Neves, Joana Roseira, Miguel F. Cunha, Bram Verstockt, Dominik Bettenworth, Diane Mege & Matthew J. Brookes. (2023) Crossing barriers: the burden of inflammatory bowel disease across Western Europe. Therapeutic Advances in Gastroenterology 16.
Crossref
Crossref
Mirabella Zhao, Sandre Lirhus, Mikael Lördal, Ebbe Langholz, Torben Knudsen, Markku Voutilainen, Marte Lie Høivik, Bjorn Moum, Karoline Anisdahl, Borghild Sæbø, Paula Haiko, Carolina Malmgren, Mehmet Coskun, Hans Olav Melberg & Johan Burisch. (2022) Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway. Alimentary Pharmacology & Therapeutics 56:6, pages 989-1006.
Crossref
Crossref
Mirabella Zhao, Lóránt Gönczi, Peter L Lakatos & Johan Burisch. (2021) The Burden of Inflammatory Bowel Disease in Europe in 2020. Journal of Crohn's and Colitis 15:9, pages 1573-1587.
Crossref
Crossref
Parambir S. DulaiVipul JairathNeeraj NarulaEmily WongGursimran S. KochharJean-Frederic ColombelWilliam J. Sandborn. (2021) A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. American Journal of Gastroenterology 116:8, pages 1709-1719.
Crossref
Crossref
Steve Halligan, Darren Boone, Lucinda Archer, Tariq Ahmad, Stuart Bloom, Manuel Rodriguez-Justo, Stuart A Taylor & Sue Mallett. (2021) Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technology Assessment 25:45, pages 1-66.
Crossref
Crossref
Sharif Yassin, Naomi Fliss Isakov, Yulia Ron, Nathaniel Aviv Cohen, Ayal Hirsch & Nitsan Maharshak. (2021) A watchful waiting approach for newly diagnosed Crohn’s disease patients with an inflammatory phenotype. International Journal of Colorectal Disease 36:4, pages 735-743.
Crossref
Crossref
Dion Wintjens, Francois Bergey, Edoardo Saccenti, Steven Jeuring, Tim van den Heuvel, Mariëlle Romberg-Camps, Liekele Oostenbrug, Ad Masclee, Vitor Martins dos Santos, Daisy Jonkers & Marie Pierik. (2021) Disease Activity Patterns of Crohn’s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort. Journal of Crohn's and Colitis 15:3, pages 391-400.
Crossref
Crossref
B. Sensi, L. Siragusa, C. Efrati, L. Petagna, M. Franceschilli, V. Bellato, A. Antonelli, C. Arcudi, M. Campanelli, S. Ingallinella, A. M. Guida & A. Divizia. (2020) The Role of Inflammation in Crohn’s Disease Recurrence after Surgical Treatment. Journal of Immunology Research 2020, pages 1-14.
Crossref
Crossref
Ji-Hao Shi, Liang Luo, Xiao-Li Chen, Yi-Peng Pan, Zhou Zhang, Hao Fang, Ying Chen, Wen-Dong Chen & Qian Cao. (2020) Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World Journal of Gastroenterology 26:41, pages 6455-6474.
Crossref
Crossref
Corinne E.G.M. Spooren, Toine M. Lodewick, Evelien M.J. Beelen, David P.J. van Dijk, Martijn J.L. Bours, Jeoffrey J. Haans, Ad A.M. Masclee, Marie J. Pierik, Frans C.H. Bakers & Daisy M.A.E. Jonkers. (2020) The reproducibility of skeletal muscle signal intensity on routine magnetic resonance imaging in Crohn's disease. Journal of Gastroenterology and Hepatology 35:11, pages 1902-1908.
Crossref
Crossref
Wing Yan Mak, Mirabella Zhao, Siew Chien Ng & Johan Burisch. (2019) The epidemiology of inflammatory bowel disease: East meets west. Journal of Gastroenterology and Hepatology 35:3, pages 380-389.
Crossref
Crossref
Julajak Limsrivilai, Satimai Aniwan, Asawin Sudcharoen, Natapat Chaisidhivej, Piyaphan Prueksapanich, Nonthalee Pausawasdi, Phunchai Charatcharoenwitthaya, Supot Pongprasobchai & Sathaporn Manassatit. (2020) Temporal trend of disease recognition, treatment paradigm, and clinical outcomes of Crohn disease in Thailand from 2000 through 2017. Medicine 99:38, pages e22216.
Crossref
Crossref
Haotian Chen, Jihao Shi, Yipeng Pan, Zhou Zhang, Hao Fang, Ying Chen, Wendong Chen & Qian Cao. (2019) Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China. Advances in Therapy 37:1, pages 431-449.
Crossref
Crossref
Johan Burisch, Gediminas Kiudelis, Limas Kupcinskas, Hendrika Adriana Linda Kievit, Karina Winther Andersen, Vibeke Andersen, Riina Salupere, Natalia Pedersen, Jens Kjeldsen, Renata D’Incà, Daniela Valpiani, Doron Schwartz, Selwyn Odes, Jóngerð Olsen, Kári Rubek Nielsen, Zsuzsanna Vegh, Peter Laszlo Lakatos, Alina Toca, Svetlana Turcan, Konstantinos H Katsanos, Dimitrios K Christodoulou, Mathurin Fumery, Corinne Gower-Rousseau, Stefania Chetcuti Zammit, Pierre Ellul, Carl Eriksson, Jonas Halfvarson, Fernando Jose Magro, Dana Duricova, Martin Bortlik, Alberto Fernandez, Vicent Hernández, Sally Myers, Shaji Sebastian, Pia Oksanen, Pekka Collin, Adrian Goldis, Ravi Misra, Naila Arebi, Ioannis P Kaimakliotis, Inna Nikuina, Elena Belousova, Marko Brinar, Silvija Cukovic-Cavka, Ebbe Langholz & Pia Munkholm. (2019) Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 68:3, pages 423-433.
Crossref
Crossref
Johan Burisch, Konstantinos H Katsanos, Dimitrios K Christodoulou, Luisa Barros, Fernando Magro, Natalia Pedersen, Jens Kjeldsen, Zsuzsanna Vegh, Peter L Lakatos, Carl Eriksson, Jonas Halfvarson, Mathurin Fumery, Corinne Gower-Rousseau, Marko Brinar, Silvija Čuković-Čavka, Inna Nikulina, Elena Belousova, Sally Myers, Shaji Sebastian, Gediminas Kiudelis, Limas Kupcinskas, Doron Schwartz, Selwyn Odes, Ioannis P Kaimakliotis, Daniela Valpiani, Renata D’Incà, Riina Salupere, Stefania Chetcuti Zammit, Pierre Ellul, Dana Duricova, Martin Bortlik, Adrian Goldis, Hendrika Adriana Linda Kievit, Alina Toca, Svetlana Turcan, Jóngerð Midjord, Kári Rubek Nielsen, Karina Winther Andersen, Vibeke Andersen, Ravi Misra, Naila Arebi, Pia Oksanen, Pekka Collin, Luisa de Castro, Vicent Hernandez, Ebbe Langholz & Pia Munkholm. (2019) Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. Journal of Crohn's and Colitis 13:2, pages 198-208.
Crossref
Crossref
B Lo, M K Vester-Andersen, I Vind, M Prosberg, M Dubinsky, C A Siegel, F Bendtsen & J Burisch. (2018) Changes in Disease Behaviour and Location in Patients With Crohn’s Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort. Journal of Crohn's and Colitis 12:3, pages 265-272.
Crossref
Crossref
Mingxia Zhou, Jing He, Yujie Shen, Cong Zhang, Jiazheng Wang & Yingwei Chen. (2017) New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease. BioMed Research International 2017, pages 1-17.
Crossref
Crossref